Literature DB >> 14592678

Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors.

Anne-Sophie Villégier1, Gérard Blanc, Jacques Glowinski, Jean-Pol Tassin.   

Abstract

Drugs of abuse, such as D-amphetamine or nicotine, are generally considered as acting through an increased release of dopamine in a subcortical structure, the nucleus accumbens, thus inducing locomotor hyperactivity in rats. Following repeated treatments, the same drugs induce a progressive increase in locomotor response called behavioral sensitization. This process has been suggested to play a role in the acquisition and maintenance of addictive behaviors. Here we show that whereas behavioral sensitization to D-amphetamine (0.5 and 0.75 mg/kg) stays constant following three consecutive periods of withdrawal (15, 30 and 30 days), the same experimental conditions completely abolish behavioral sensitization to 0.3 and 0.5 mg/kg nicotine. Indeed, following these periods of withdrawal, locomotor responses to nicotine are identical to those obtained at the first nicotine injection or after repeated saline injections. However, when a monoamine oxidases inhibitor (MAOI), tranylcypromine (3 mg/kg) or pargyline (30 mg/kg), is co-injected with nicotine, behavioral sensitization is maintained despite submission of the animals to the same withdrawal experimental design. Since tobacco smoke is known to contain many compounds including MAOIs, our data suggest that addictive properties of tobacco may not be limited to nicotine. We propose that MAOIs potentiate effects of nicotine on monoamines release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592678     DOI: 10.1016/s0091-3057(03)00223-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  21 in total

Review 1.  Nicotine reduction revisited: science and future directions.

Authors:  Dorothy K Hatsukami; Kenneth A Perkins; Mark G Lesage; David L Ashley; Jack E Henningfield; Neal L Benowitz; Cathy L Backinger; Mitch Zeller
Journal:  Tob Control       Date:  2010-10       Impact factor: 7.552

Review 2.  Brexpiprazole: so far so good.

Authors:  Saibal Das; Preeti Barnwal; Blessed Winston A; Somnath Mondal; Indranil Saha
Journal:  Ther Adv Psychopharmacol       Date:  2016-02

3.  Nicotine as a typical drug of abuse in experimental animals and humans.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2005-10-05       Impact factor: 4.530

4.  Markov model of smoking cessation.

Authors:  Peter R Killeen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-20       Impact factor: 11.205

5.  Tobacco smoke containing high or low levels of nicotine during adolescence: effects on novelty-seeking and anxiety-like behaviors in mice.

Authors:  Yael Abreu-Villaça; Cláudio C Filgueiras; Monique Correa-Santos; Cristiane C Cavina; Victor F Naiff; Thomas E Krahe; Alex C Manhães; Anderson Ribeiro-Carvalho
Journal:  Psychopharmacology (Berl)       Date:  2014-11-18       Impact factor: 4.530

6.  The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition.

Authors:  Shahrdad Lotfipour; Monica M Arnold; Derk J Hogenkamp; Kelvin W Gee; James D Belluzzi; Frances M Leslie
Journal:  Neuropharmacology       Date:  2011-03-23       Impact factor: 5.250

7.  Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine.

Authors:  Tracy T Smith; Laura E Rupprecht; Samantha N Cwalina; Matthew J Onimus; Sharon E Murphy; Eric C Donny; Alan F Sved
Journal:  Neuropsychopharmacology       Date:  2016-03-09       Impact factor: 7.853

Review 8.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

Review 9.  Genetics of nicotine dependence and pharmacotherapy.

Authors:  Christina N Lessov-Schlaggar; Michele L Pergadia; Taline V Khroyan; Gary E Swan
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

10.  Age influences the effects of nicotine and monoamine oxidase inhibition on mood-related behaviors in rats.

Authors:  Anne-Sophie Villégier; Brittney Gallager; Jon Heston; James D Belluzzi; Frances M Leslie
Journal:  Psychopharmacology (Berl)       Date:  2010-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.